Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Companies Involved in Therapeutics Development
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Drug Profiles
AP-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBR-760 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Ipsen presents data on Somatuline Autogel at ISPOR Europe 2019
Jul 12, 2019: Zucara Therapeutics secures grant from GlycoNet to expand and validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Jun 24, 2019: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for Somatuline Depot (lanreotide)
May 24, 2019: New investigational clinical data for Ipsens oncology products including lanreotide acetate in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting
May 24, 2019: Ipsen to present on Somatuline at 2019 ASCO Annual Meeting
May 21, 2019: Crinetics Pharmaceuticals initiates phase 1 study of CRN01941 for the treatment of neuroendocrine tumors
Mar 19, 2019: Crinetics Pharmaceuticals doses first patients in phase 2 clinical trials of CRN00808 for acromegaly
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on drug candidate CRN-00808 at ENDO2019
Mar 06, 2019: Ipsen to present improvements to Somatuline Autogel pre-filled syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Feb 28, 2019: Ipsen to present new data on enhancement of patient care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Oct 12, 2018: Ipsen to present data on Lanreotide at ESMO 2018
Oct 05, 2018: Ipsen presents data on Somatuline depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amryt Pharma Plc, H2 2019
Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Enteris BioPharma Inc, H2 2019
Pipeline by GlyTech Inc, H2 2019
Pipeline by Ipsen SA, H2 2019
Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Pipeline by Strongbridge Biopharma plc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Tiburio Therapeutics Inc, H2 2019
Pipeline by Zucara Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
【掲載企業】
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc